NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 133 filers reported holding NEKTAR THERAPEUTICS in Q2 2024. The put-call ratio across all filers is 1.69 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $338 | -5.1% | 597 | 0.0% | 0.00% | – |
| Q3 2023 | $356 | +3.5% | 597 | 0.0% | 0.00% | – |
| Q2 2023 | $344 | -18.1% | 597 | 0.0% | 0.00% | – |
| Q1 2023 | $420 | -68.9% | 597 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $1,350 | -29.4% | 597 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $1,911 | -15.8% | 597 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,269 | -29.5% | 597 | 0.0% | 0.00% | -33.3% |
| Q1 2022 | $3,218 | -60.1% | 597 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $8,066 | – | 597 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,000,000 | $69,480,000 | 3.98% |
| MAVERICK CAPITAL LTD | 5,186,637 | $120,123,000 | 2.53% |
| Rhenman & Partners Asset Management AB | 790,000 | $18,296,000 | 1.98% |
| Goodman Financial Corp | 121,439 | $2,813,000 | 1.41% |
| Bellevue Group AG | 3,535,013 | $81,871,000 | 1.16% |
| Gs Investments, Inc. | 54,200 | $1,255,272,000 | 1.00% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 493,586 | $11,431,000 | 0.83% |
| RICE HALL JAMES & ASSOCIATES, LLC | 565,833 | $13,105,000 | 0.56% |
| DCF Advisers, LLC | 43,000 | $996,000 | 0.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,499,000 | 0.50% |